Plato Investment Management Ltd Invests $1.49 Million in Biogen Inc. $BIIB

Plato Investment Management Ltd acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 6,938 shares of the biotechnology company’s stock, valued at approximately $1,490,000.

Several other institutional investors have also added to or reduced their stakes in the stock. LSV Asset Management boosted its position in shares of Biogen by 3.3% during the fourth quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company’s stock worth $55,756,000 after buying an additional 9,976 shares during the period. Orbimed Advisors LLC bought a new position in shares of Biogen during the first quarter worth about $11,293,000. Catalyst Funds Management Pty Ltd acquired a new stake in Biogen in the 4th quarter valued at approximately $2,006,000. Systematic Financial Management LP raised its position in Biogen by 256.3% in the 4th quarter. Systematic Financial Management LP now owns 16,640 shares of the biotechnology company’s stock valued at $2,928,000 after buying an additional 11,970 shares during the last quarter. Finally, Contrarius Group Holdings Ltd bought a new stake in Biogen in the 4th quarter valued at approximately $11,431,000. 87.93% of the stock is owned by institutional investors.

Biogen Stock Down 0.3%

BIIB stock opened at $209.15 on Tuesday. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. The business has a 50 day moving average price of $204.09 and a two-hundred day moving average price of $193.49. The company has a market cap of $30.90 billion, a price-to-earnings ratio of 37.02, a P/E/G ratio of 6.48 and a beta of 0.17. Biogen Inc. has a twelve month low of $131.52 and a twelve month high of $219.72.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The company had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The business’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Analysts anticipate that Biogen Inc. will post 12.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BIIB. Needham & Company LLC upped their price target on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a research report on Monday, June 22nd. Zacks Research raised shares of Biogen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. Wedbush increased their target price on shares of Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, July 30th. Finally, Sanford C. Bernstein decreased their target price on shares of Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $227.07.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.